87708-16-5

Basic information

• Product Name: BRN 4480560
• Synonyms: BRN 4480560;3-OxazolidinesulfonaMide, 2-oxo-N-phenyl-;2-oxo-N-phenyloxazolidine-3-sulfonamide
• CAS NO: 87708-16-5
• Molecular Formula: C₉H₁₀N₂O₄S
• Molecular Weight: 242.2517
• Mol File: 87708-16-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 146-148 °C
• Boiling Point: 376.3°Cat760mmHg
• Flash Point: 181.4°C
• Appearance: /
• Density: 1.53g/cm³
• Vapor Pressure: 7.33E-06mmHg at 25°C
• Refractive Index: 1.637
• PKA: 7.14±0.20(Predicted)
• CAS DataBase Reference: BRN 4480560(CAS DataBase Reference)
• NIST Chemistry Reference: BRN 4480560(87708-16-5)
• EPA Substance Registry System: BRN 4480560(87708-16-5)

Safety Data

• Hazardous Substances Data: 87708-16-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H10N2O4S/c12-9-11(6-7-15-9)16(13,14)10-8-4-2-1-3-5-8/h1-5,10H,6-7H2

Upstream product

• 1189-71-5 isocyanate de chlorosulfonyle 
• 62-53-3 aniline 
• 540-51-2 2-bromoethanol 
• 87708-04-1 N-(chloro-2 ethoxycarbonyl) N'-(phenyl) sulfamide 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 1245920-58-4 C₁₇H₂₀N₂O₂S 
• 69705-83-5 N-isopropyl-N'-phenyl-sulfamide 
• 587-14-4 N,N'-diphenylsulfamide 

Relevant articles and documents

Histone deacetylase inhibitors and its preparation method and use thereof

The invention discloses a histone deacetylase inhibitor and its preparation method and use, the invention discloses a compound of the formula I as shown, or its crystalline form, or its pharmaceutically acceptable salt, or solvate thereof, or prodrug thereof, or its metabolic product. The invention of the formula I illustrated new compound, has shown good deacetylase inhibition activity, with the histone deacetylase for clinical treatment of diseases associated with abnormal activity of a new pharmaceutical may be.

FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF

This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

Copper-catalyzed oxidative amination and allylic amination of alkenes

Enamines and enamides are useful synthetic intermediates and common components of bioactive compounds. A new protocol for their direct synthesis by a net alkene C-H amination and allylic amination by using catalytic Cu II in the presence of MnO2 is reported. Reactions between N-aryl sulfonamides and vinyl arenes furnish enamides, allylic amines, indoles, benzothiazine dioxides, and dibenzazepines directly and efficiently. Control experiments further showed that MnO2 alone can promote the reaction in the absence of a copper salt, albeit with lower efficiency. Mechanistic probes support the involvement of nitrogen-radical intermediates. This method is ideal for the synthesis of enamides from 1,1-disubstituted vinyl arenes, which are uncommon substrates in existing oxidative amination protocols. A new protocol for the direct synthesis of enamides and allylic amines by oxidative N-H/C-H coupling of N-sulfonylanilines with vinylarenes is presented. The reaction works in both inter- and intramolecular modes and is catalyzed by copper salts by using MnO2 as the stoichiometric oxidant (see scheme). Nitrogen heterocycles including indoles, benzothiazine dioxides, and dibenzazepines can be formed. Copyright